OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx is attractive because its business is shifting from lower-margin managed services toward a higher-margin, data-driven platform, with EBITDA margin expanding from ~13% in 2024 to 24% in 2Q26 even as revenue reset. Its proprietary point-of-care network reaches more than 2M HCPs and 240M patients, while DAAP grew +30% Y/Y in 2Q and roughly 30% of DAAP deals now run at about a 90% gross margin, supporting durable operating leverage. Balance-sheet de-risking through the May 2026 refinance, net cash of $5.1M, and the DeepIntent integration expected to begin contributing in 4Q and scale into the 2027 renewal cycle provide additional upside catalysts.

OptimizeRx is under pressure because its revenue model remains highly concentrated, exposed to pharma budget cuts, policy shifts like MFN and IRA pricing pressure, and dependence on a small set of customers and partners. 2Q26 revenue fell 30% year over year to $20.5M after a low-margin managed-service winddown and zero revenue from a customer that had been ~10% of 2025 revenue, while net revenue retention dropped to 90%, signaling weaker expansion. Although EBITDA margin improved to 24.1% and cash generation remained strong, the company’s 2026 outlook still depends on a steep 4Q ramp to 35%–40% of annual sales, leaving execution risk elevated.